Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | HRH1 | P35367 | 2/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.72 |
| ▸ | DRD3 | P35462 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | HRH2 | P25021 | 1/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857332 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2865623 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL6652138 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Oxalic Acid SCHEMBL5188469 | 0.94 | SLC6A4 (0.88) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL141623 | 0.91 | SLC6A4 (0.83) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL7375135 | 0.89 | SLC6A4 (0.80) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL12780358 | 0.87 | SLC6A4 (0.78) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2615213 | 0.87 | SLC6A4 (0.78) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2868968 | 0.86 | SLC6A4 (0.76) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL13234952 | 0.86 | SLC6A4 (0.84) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009515-A1 | Process and intermediates for preparing escitalopram | TORCAN CHEMICAL LTD (CA) | 2006-01-12 | — | — | US | claimed |
| EP-1479673-A1 | METHOD OF OBTAINING CITALOPRAM | ESTEVE QUIMICA, S.A. (ES) | 2004-11-24 | — | — | EP | claimed |
| US-6635773-B2 | Purification by selective extraction of citalopram or its impurities using organic solvents and water, and the process for preparing citalopram salts | ESTEVE QUIMICA, S.A. (ES) | 2003-10-21 | — | — | US | claimed |
| US-20030144534-A1 | Process for preparing citalopram | ESTEVE QUIMICA, S.A (ES) | 2003-07-31 | — | — | US | claimed |
| US-10351552-B2 | Bicyclic antiparasitic compounds | MediSynergies, LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-1896439-B2 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | LUNDBECK & CO AS H (DK) | 2014-10-15 | — | — | EP | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-1169314-B2 | PROCESS FOR THE MANUFACTURE OF SALTS OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2011-06-01 | — | — | EP | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110065938-A1 | METHOD FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2011-03-17 | — | — | US | disclosed |
| US-7834201-B2 | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | disclosed |
| US-20020077353-A1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2002-06-20 | — | — | US | disclosed |
| CN-1339435-A | Process for the preparation of citalopram | LUNDBECK & CO AS H (DK) | 2002-03-13 | — | — | CN | disclosed |
| WO-2002016341-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
| US-20020025982-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | US | disclosed |
| EP-1159274-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001002383-A2 | PROCESS FOR THE SYNTHESIS OF CITALOPRAM | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000013648-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-16 | — | — | WO | disclosed |
| US-4136193-A | ANTI-DEPRESSIVE SUBSTITUTED 1-DIMETHYLAMINOPROPYL-1-PHENYL PHTHALANS | KEFALAS A/S (DK) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351552-B2 | Bicyclic antiparasitic compounds | TBCA, NAT1, HDAC1 | SLC6A4 1612/4885SLC6A2 289/4885HTR2C 2121/4885 |
| US-20110065938-A1 | METHOD FOR THE PREPARATION OF ESCITALOPRAM | GSK3B, GSK3A, SLC6A4 | SLC6A4 3/4885SLC6A2 9/4885HTR2C 20/4885 |
| US-20020077353-A1 | Method for the preparation of citalopram | MAOB, MAOA, CYP4F3 | SLC6A4 43/4885SLC6A2 34/4885HTR2C 71/4885 |
| US-20020025982-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | MAOB, SLC6A4, CYP2D6 | SLC6A4 2/4885SLC6A2 32/4885HTR2C 27/4885 |
| US-20030144534-A1 | Process for preparing citalopram | MAOB, MAOA, CMA1 | SLC6A4 39/4885SLC6A2 43/4885HTR2C 180/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SLC6A4 3269/4885SLC6A2 3188/4885HTR2C 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.